Ascentage Pharma to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting

Reuters

2025/11/04

<a href="https://laohu8.com/S/AAPG">Ascentage Pharma</a> to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting

Ascentage Pharma Group International has announced that results from multiple clinical and preclinical studies involving its investigational drug candidates-olverembatinib, lisaftoclax, and APG-5918-will be presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6 to December 9, 2025, in Orlando, Florida. Among these, an oral presentation will feature the latest findings from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have failed prior Bruton's tyrosine kinase inhibitor (BTKi) treatments. Additional data on lisaftoclax in combination with azacitidine for newly diagnosed or prior venetoclax-exposed myeloid malignancies will also be presented in a poster session. The results have not yet been presented and are scheduled for future disclosure at the ASH meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580205632"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580205632\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580205632?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 08:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580205632","market":"fut","top_or_hot":-1,"title":"Ascentage Pharma to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AAPG\">Ascentage Pharma</a> to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASPHF\">Ascentage Pharma</a> Group International has announced that results from multiple clinical and preclinical studies involving its investigational drug candidates-olverembatinib, lisaftoclax, and APG-5918-will be presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6 to December 9, 2025, in Orlando, Florida. Among these, an oral presentation will feature the latest findings from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have failed prior Bruton's tyrosine kinase inhibitor (BTKi) treatments. Additional data on lisaftoclax in combination with azacitidine for newly diagnosed or prior venetoclax-exposed myeloid malignancies will also be presented in a poster session. The results have not yet been presented and are scheduled for future disclosure at the ASH meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 08:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/AAPG\">Ascentage Pharma</a> to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASPHF\">Ascentage Pharma</a> Group International has announced that results from multiple clinical and preclinical studies involving its investigational drug candidates-olverembatinib, lisaftoclax, and APG-5918-will be presented at the 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6 to December 9, 2025, in Orlando, Florida. Among these, an oral presentation will feature the latest findings from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have failed prior Bruton's tyrosine kinase inhibitor (BTKi) treatments. Additional data on lisaftoclax in combination with azacitidine for newly diagnosed or prior venetoclax-exposed myeloid malignancies will also be presented in a poster session. The results have not yet been presented and are scheduled for future disclosure at the ASH meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL7wKpRB:1","article_id":"2580205632","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580205632","pubTimestamp":1762215460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascentage Pharma Group International has announced that results from multiple clinical and preclinical studies involving its investigational drug candidates-olverembatinib, lisaftoclax, and APG-5918-will be presented at the 67th American Society of Hematology  Annual Meeting, scheduled for December 6 to December 9, 2025, in Orlando, Florida. Among these, an oral presentation will feature the latest findings from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma  who have failed prior Bruton's tyrosine kinase inhibitor  treatments. Additional data on lisaftoclax in combination with azacitidine for newly diagnosed or prior venetoclax-exposed myeloid malignancies will also be presented in a poster session. The results have not yet been presented and are scheduled for future disclosure at the ASH meeting.Disclaimer: This news brief was created by Public Technologies  using generative ar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","06855":"亚盛医药-B","BK1161":"生物科技"},"translate_title":"亚盛医药将在2025年ASH会议上公布Lisaftoclax II期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":0.9},"content_text":"Ascentage Pharma to Present Phase II Lisaftoclax Trial Results at 2025 ASH Meeting\n    \n\nAscentage Pharma Group International has announced that results from multiple clinical and preclinical studies involving its investigational drug candidates-olverembatinib, lisaftoclax, and APG-5918-will be presented at the 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6 to December 9, 2025, in Orlando, Florida. Among these, an oral presentation will feature the latest findings from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have failed prior Bruton's tyrosine kinase inhibitor (BTKi) treatments. Additional data on lisaftoclax in combination with azacitidine for newly diagnosed or prior venetoclax-exposed myeloid malignancies will also be presented in a poster session. The results have not yet been presented and are scheduled for future disclosure at the ASH meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on November 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}